JLE

Hépato-Gastro & Oncologie Digestive

MENU

Traitement adjuvant de l’adénocarcinome du pancréas : une lente évolution depuis 2001, une révolution en 2018 Volume 26, numéro 4, Avril 2019

  • [1] Cowppli-Bony A., Uhry Z., Remontet L. Survival of solid cancer patients in France, 1989-2013: a population-based study. Eur J Cancer Prev. 2017;26:461-468.
  • [2] Rahib L, Smith B.D., Aizenberg R. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
  • [3] Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:2140-2141.
  • [4] Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-10.
  • [5] Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013 ; 310 : 1473-81.
  • [6] Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010 ; 304 : 1073-81.
  • [7] Farrell J.J., Elsaleh H., Garcia M. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187-195.
  • [8] Svrcek M., Cros J., Maréchal R. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Histopathology. 2015;66:457-462.
  • [9] Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non- inferiority trial (JASPAC 01). Lancet 2016 ; 388 : 248-57.
  • [10] Sinn M., Liersch T., Gellert K. CONKO-006: a randomized double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo for patients with R1-resection of pancreatic cancer. Onkologie. 2011;34:59-159.
  • [11] Sinn M., Bahra M., Liersch T. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer : a multicenter randomized phase III trial. J Clin Oncol. 2017;35:3330-3337.
  • [12] Wisniewski M., Placide P.A., Granier S. Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma : is there a role for erlotinib?- review of the open label phase III trial CONKO 005. HepatoBiliary Surg Nutr. 2018;7:399-402.
  • [13] Moore M.J., Goldstein D., Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
  • [14] Wacker B., Nagrani T., Weinberg J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13:3913-3921.
  • [15] Neuzillet C, Gaujoux S, Williet N, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018:18 ; S1590-8658(18)30888-0) ; www.tncd.org/www.snfge.org.
  • [16] Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
  • [17] Klinkenbijl J.H., Jeekel J., Sahmoud T. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-784.
  • [18] Badiyan SN, Molitoris JK, Chuong MD, et al. The role of radiation therapy for pancreatic cancer in the adjuvant and neoadjuvant settings. Surg Oncol Clin N Am 2017 ; 26 : 431-453.
  • [19] Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 Study. J Clin Oncol 2014 ; 3 : 504-12.
  • [20] Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 2017 ; 389 : 1011-24.
  • [21] Conroy T., Gourgou S., Malka D. Traitement adjuvant du cancer du pancréas : CAP ou pas CAP ? Hépato-Gastro et Oncologie Digestive. 2017;24:532-538.
  • [22] Conroy T1, Desseigne F., Ychou M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
  • [23] Conroy T., Hammel P., Hebbar M. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. N Engl J Med. 2018;379:2395-2406.
  • [24] Kindler H. A Glimmer of hope for pancreatic cancer. N Engl J Med. 2018;379:2463-2464.